Type 2 diabetes
Conditions
Interventions
oral semaglutide group
control group
Sponsors
Dokkyo Medical University Department of Endocrinology and Metabolism
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Type 2 diabetes who have inadequate glycemic control(HbA1c between 6.5 and 12.4 %) under medical treatment by dieting and exercise cure and/or drug treatment. 2)Over 20 years old and less than 80 years old 3)Sex unquestioned 4)Patients with no history of cardiovascular disease 5)No treatment or treatment with stable doses of antihypertensive and antiplatelet agents for at least 3 months prior to randomization. 6)The patient who gives a written informed
Exclusion criteria
Exclusion criteria: 1)Type 1 diabetes 2)Liver dysfunction (hepatic enzymes more than three times the upper limit of normal ranges) 3)A pregnant woman and/or a woman under breast-feeding 4)Impaired kidney function (serum crearinine greater than 1.3 mg/dl in men, 1.2 mg/dl in women) 5)Diabetic proliferative retinopathy 6)The patients who has an anamnesis of hypersensitivity to the ingredient of a trial drug 7)No treatment with other GLP-1R analogue 8)Patient with intolerance of medical reasons by doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight change after 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in HbA1c, urinary albumin (UACR), and blood pressure after 24 weeks BNP, body composition, electrocardiogram (CVR-R), serum HMV adiponectin, serum sDPP-4 (sCD26), DTBQ score changes PAI-1, TAT, PIC, insulin, C-peptide, glucagon, blood amino acid fraction | — |
Countries
Japan
Contacts
Public ContactTeruo Jojima
Dokkyo Medical University Department of Endocrinology and Metabolism
Outcome results
None listed